Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Denmark / NCT03946410
Active, not recruiting Not applicable

Danish Cardiovascular Screening Trial II

NCT03946410 · tracked via the Priya Life Science Denmark tracker
Sponsor
Odense University Hospital
Phase
Not applicable
Started
2017-08-01
Last updated
2025-02-26

Condition(s) studied

Cardiac DiseaseVascular Diseases

Investigational drug(s) / intervention(s)

Invitation to screening

Invitation to screening: Invitation to CVD screening with non contrast CT scanning, ABI measurement and blood tests

Study summary

This study attempts to reduce social inequality in cardiovascular health by performing an interventional screening trial on how best to decrease cardiovascular disease (CVD) among people with low social status.

Eligibility

Sex
MALE
Min age
60 Years
Max age
64 Years
Healthy volunteers
No
Inclusion Criteria: * Men aged 60-64 living in the municipalities of Funen, Silkeborg, Vejle and surrounding municipailties Exclusion Criteria: * Men not aged 60-64 * Men not living in the mentioned municipalities * Women

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
Odense University Hospital Odense Denmark
Region Hospital Silkeborg Silkeborg Denmark
Svendborg Sygehus Svendborg Denmark
Vejle Sygehus Vejle Denmark

More Odense University Hospital trials in Denmark

Vitamin D and Angiogenic Markers in Odense Child Cohort 1 Active, not recruiting
Methylphenidate in Pediatric Brain Tumor Survivors With Cancer-related Fatigue Recruiting
The Safe Fast Track Study Recruiting
Severe Lung Disease in Childhood Recruiting
Continuous Bloodsugar Monitoring System With a Sensor Compared to Fingerstick Bloodsugar Monitoring Recruiting

Other trials for the same condition

Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease Recruiting
PROficiency Based StePwise Endovascular Curricular Training: Multicentric Registry Recruiting
Echocardiography in Men With Erectile Dysfunction Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03946410 on ClinicalTrials.gov ↗ ← All trials in Denmark